Royal Fund Management LLC Has $261,000 Stock Position in Gilead Sciences, Inc. $GILD

Royal Fund Management LLC reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 79.6% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,876 shares of the biopharmaceutical company’s stock after selling 7,305 shares during the period. Royal Fund Management LLC’s holdings in Gilead Sciences were worth $261,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Vermillion & White Wealth Management Group LLC grew its position in Gilead Sciences by 71.4% in the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 85 shares in the last quarter. Strategic Investment Solutions Inc. IL bought a new stake in Gilead Sciences in the fourth quarter worth $25,000. Quattro Advisors LLC acquired a new position in Gilead Sciences during the fourth quarter worth $26,000. Wealth Preservation Advisors LLC increased its position in Gilead Sciences by 60.0% during the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 81 shares during the last quarter. Finally, Ares Financial Consulting LLC acquired a new stake in shares of Gilead Sciences in the fourth quarter worth about $28,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Wall Street Zen raised Gilead Sciences from a “hold” rating to a “buy” rating in a report on Sunday, July 12th. Daiwa Securities Group lowered their price target on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating on the stock in a report on Tuesday, May 19th. Truist Financial reduced their price objective on shares of Gilead Sciences from $157.00 to $156.00 and set a “buy” rating for the company in a research note on Tuesday, July 7th. Royal Bank Of Canada decreased their price objective on shares of Gilead Sciences from $122.00 to $120.00 and set a “sector perform” rating for the company in a report on Tuesday, July 7th. Finally, Barclays lowered their target price on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a research note on Wednesday. Twenty-five equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $157.93.

Gilead Sciences Trading Down 1.1%

Shares of GILD stock opened at $131.28 on Friday. Gilead Sciences, Inc. has a 1 year low of $108.46 and a 1 year high of $157.29. The firm’s fifty day simple moving average is $129.70 and its 200 day simple moving average is $135.91. The firm has a market capitalization of $162.99 billion, a P/E ratio of 17.89 and a beta of 0.32. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The company had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.91 billion. During the same period last year, the business posted $1.81 EPS. The business’s quarterly revenue was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, sell-side analysts predict that Gilead Sciences, Inc. will post -0.78 EPS for the current year.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: European regulators issued a positive opinion supporting expanded use of Trodelvy with Keytruda in certain patients with advanced triple-negative breast cancer. The decision strengthens Gilead’s oncology opportunity and may improve confidence in Trodelvy’s growth prospects. Gilead Sciences Following Trodelvy Progress and a Fair Value Debate
• Positive Sentiment: UBS reiterated a Buy rating and a $175 price target, citing Gilead’s long-acting HIV pipeline and advances in pre-exposure prophylaxis (PrEP) as drivers of durable growth. HIV franchise strength, Yeztugo expectations and oncology progress are also highlighted ahead of the earnings report. UBS Reiterates Buy on Gilead
• Neutral Sentiment: Analyst coverage remains generally bullish, and several valuation articles describe GILD as potentially inexpensive after its strong five-year performance. However, investors remain divided over how much of the company’s future growth is already reflected in the shares. Do Wall Street Analysts Like Gilead Sciences Stock?
• Neutral Sentiment: Second-quarter earnings previews focus on revenue, earnings and operating metrics rather than reporting new results. A favorable quarter could clarify recent estimate and valuation concerns, while investors are likely to watch HIV sales, Yeztugo adoption potential, Trodelvy and cell therapy performance closely. Gilead to Report Q2 Earnings
• Negative Sentiment: Barclays lowered its price target from $155 to $145 and maintained an Equal Weight rating, signaling less near-term upside confidence. Analysts also cite competitive pressure in cell therapy, while Atea Pharmaceuticals reported positive hepatitis C trial data that could eventually challenge Gilead’s HCV franchise. Barclays Price Target Update

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $125.40, for a total value of $376,200.00. Following the completion of the sale, the chief financial officer owned 171,646 shares in the company, valued at approximately $21,524,408.40. This trade represents a 1.72% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $131.46, for a total value of $1,971,900.00. Following the sale, the chief executive officer directly owned 617,567 shares in the company, valued at $81,185,357.82. The trade was a 2.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 67,000 shares of company stock valued at $8,687,140 in the last quarter. Corporate insiders own 0.30% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.